Shadick, Nancy
Hagino, Owen
Praestgaard, Amy
Fiore, Stefano
Weinblatt, Michael
Burmester, Gerd
Funding for this research was provided by:
sanofi
Regeneron Pharmaceuticals
Article History
Received: 16 September 2022
Accepted: 15 May 2023
First Online: 27 May 2023
Declarations
:
: The study protocol and informed consent documents were reviewed and approved by the institutional review board of Brigham and Women’s Hospital (approval number: 2002P001762).
: Not applicable.
: NS received research grant support from BMS, Amgen, Eli Lilly, Mallinckrodt, Sanofi-Regeneron, and Crescendo Biosciences; OH, AP, and SF are employees of Sanofi and may hold stock/stock options in the company; MW received consultation fees from AbbVie, Aclaris, Amgen, Arena, Bayer, Bristol Myers Squibb, Corvitas, Eqrx, Genosco, GSK, Gilead, Horizon, Johnson & Johnson, Kiniksa, Eli Lilly, Novartis, Pfizer, Rami Therapeutics, R Pharma, Roche, Sanofi, Scipher, Sci Rhom, Set Point, and Tremeau; may hold stock/stock options of CanFite, Inmedix, Vorso, and Scipher. Received grant support from Amgen, Bristol Myers Squibb, Eli Lilly, and Sanofi; GB received grants/contracts from AbbVie, Eli Lilly, Merck Sharp & Dohme, Pfizer, Roche, Sanofi, and UCB and honoraria from AbbVie, Eli Lilly, Merck Sharp & Dohme, Pfizer, Roche, Sanofi, and UCB.